arrow
M

Marie K. Kirby

Centers for Disease Control and Prevention
H指数:18
被引数:2,125

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Supporting molecular detection of A(H5N1) through development and characterization of RNA reference materials

通过RNA参考材料的开发与表征支持A(H5N1)的分子检测

2026-07-220
OAAI
Influenza Vaccine Effectiveness Against Outpatient Acute Respiratory Illness With Laboratory-confirmed Influenza, United States, 2024–2025 Season

2024–2025流行季美国实验室确诊流感的门诊急性呼吸道疾病的流感疫苗有效性

2026-07-140
PRE
Pediatric Vaccine Effectiveness Against Influenza Hospitalization and Outpatient Visits: 2021-2024

儿童疫苗预防流感住院和门诊就诊的效果:2021-2024

2026-05-011
PRE
Next-Generation Sequencing Strategies During the 2024–2025 Avian Influenza A(H5N1) Emergency Response in the U.S

2024–2025年美国禽流感A(H5N1)应急响应期间的下一代测序策略

Viruses
IF3.5
2026-04-220
OAAI
Development and Characterization of Candidate Vaccine Viruses against High Pathogenicity Avian Influenza A(H5) Viruses for Rapid Pandemic Response

针对高致病性禽流感A(H5)病毒快速大流行应对的候选疫苗病毒的开发与表征

2026-02-280
OA
Influenza mRNA vaccine reduces pathogenicity and transmission of A(H5N1) virus in a ferret model

流感mRNA疫苗在雪貂模型中降低了A(H5N1)病毒致病性和传播性

2025-11-290
OAAI
Antiviral susceptibility monitoring: testing algorithm, methods, and findings for influenza season, 2023-2024

抗病毒敏感性监测:2023-2024流感季节的检测算法、方法和结果

2025-10-110
PRE
Impact of naturally occurring hemagglutinin substitutions on antigenicity and fitness of influenza A(H5N1) virus

自然发生的血凝素替换对甲型H5N1流感病毒抗原性和适应性的影响

2025-10-021
OAAI
Human infections with highly pathogenic avian influenza A(H5N1) viruses in the United States from March 2024 to May 2025

M. A. Rolfes et al., Nat. Med. 10.1038/s41591-025-03905-2 (2025).

2025-07-250
PRE
Influenza Vaccine Effectiveness Against Medically Attended Outpatients Illness, United States, 2023-2024 Season
2025-01-065
OA
An influenza mRNA vaccine protects ferrets from lethal infection with highly pathogenic avian influenza A(H5N1) virus
2024-12-180
PRE
Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves

在整个Delta到Omicron波中,美国循环和新兴SARS-CoV-2变体的抗原表征

2024-05-074
OAAI
Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants( vol 28 , pg 1083 , 2022)
2023-11-091
OAAI
Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants
2022-02-07151
OAAI
Epidemiologic Characteristics Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen-Based Test Results, Real-Time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) Cycle Threshold Values, Subgenomic RNA, and Viral Culture Results From University Testing
2021-04-1226
OAAI